新背景下英国国家卫生和临床技术优化研究所的转型

Transition of NICE in UK New Reform Background

2010年年底,英国卫生部做出重大决定:英国未来药品的市场准入评价将不再依赖英国知名医药技术评价机构—英国国家卫生和临床技术优化研究所,将主要依靠一个以价值为基础的药品定价体系。英国卫生部的这个决定无疑将对临床技术评价研究所的未来发展和定位产生深远影响。纵观临床技术评价研究所成立至今走过的道路,结合目前英国医疗改革的形势,描述了临床技术评价研究所及其利益相关各方与这个政治决策的关系,总结了目前英国国内对临床技术评价研究所未来走向的讨论,并简单探讨了该决定对国际医药技术评价界的影响。

At the end of 2010,the Department of Health in UK made the decision that the new drug evaluation work would no longer rely on the National Institute of Health and Clinical Excellence（NICE）,but be shifted to a so-called ＂value-based system＂.The UK health authorities＇ decision will definitely have great far-reaching impact on the future development and positioning of NICE.By taking a retrospective view of NICE＇s development and considering the new changes of its role in the new round of health reform in UK,the paper will depict NICE and its key stakeholders＇ roles in making this decision,summarize the discussions about NICE＇s future development and briefly explore its impact on the global community of health technology evaluation.